Medlab (ASX:MDC) receives government grant to apply

  • NSW Government grant received on 23rdrd December 2021 to develop a “non-puncture” vaccine solution
  • Medlab collaborates with UNSW and MQ University (two leading global academic and R&D institutions)
  • This NanoCelle® the non-invasive nasally administered vaccine is considered a “first in class” drug delivery system
  • This collaboration between government grants and universities solidifies Medlab’s transition to a true biotechnologies business.
  • Overall relevance expectation is extremely high
  • NanoCelle® because an asset has not yet been rated in analyst reports

SYDNEY, Jan. 14, 2022 (GLOBE NEWSWIRE) — Medlab Clinic Ltd. (ASX:MDC) is pleased to announce in collaboration with Prof. Pall Thordarson (Director of the UNSW RNA Institute, UNSW) and Prof. Daniela Traini (NHMRC Researcher, Biomedical Sciences, Macquarie University and The Woolcock Institute of Medical Research) has been awarded a grant from the NSW Government to develop a proof-of-concept NanoCelle® Nasal RNA vaccine as part of Australia’s need to develop innovative infrastructure and manufacturing for the ongoing fight against COVID-19.

Professor Pall Thordarson is the Program Coordinator of the NSW RNA Production and Research Network (NSW-RPRN), which is funded by NSW Health. He also led the RNA BioScience Alliance and worked in an advisory capacity to the New South Wales government.

Professor Daniela Traini is Professor of Respiratory Sciences at the Woolcock Institute and MQ and an expert in inhaled drug development. She is a member of the NSW-RPRN and sits on its management committee.

Dr. Sean Hall, CEO of Medlab (ASX:MDC) said “We are extremely satisfied with this result. Personally, I would like to thank Research Australia for making the presentations, secondly, I warmly thank welcome the two professors and their respective teams, who are recognized academics in the field of nucleic acids production (RNA) and nasal administration of pharmaceutical agents. This grant and the collaboration with our university partners offer a welcome solution to patients as well as aa risk-free mechanism to spearhead NanoCelle® in complex vaccine technologies.

Dr Hall also added, “the ability to prove the effectiveness of administering vaccines without the ‘prick’ is a serious problem game changer for modern medicine – we are thrilled to be part of that and welcome the potential commercial Opportunities forward.”

NanoCelle® is a patented submicron delivery platform (now patented by Medlab in 43 countries) used to improve medicines. More information can be found here:


Authorisation & Additional information

This announcement has been authorized by the Board of Directors of Medlab Clinical Limited.

On medical laboratory Clinical:

Medlab Clinical Ltd (ASX:MDC) is at the forefront of developing and commercializing a delivery platform, enabling improved medical properties including efficacy, safety, compliance and patient stability. Medlab’s pipeline includes a number of small and large molecules ranging from repurposing generic drugs to improving the delivery of immunotherapies. The lead patented drug candidate NanaBis was developed for cancerous bone pain as a viable alternative to opioid use. Data to date strongly suggests NanaBis may be equally effective in non-cancer neuropathic pain. NanoCelle®, the patented delivery platform is 100% owned by Medlab and developed in Medlab’s OGTR registered laboratory. NanoCelle® is designed to address known medication issues, addressing global unmet medical needs. Medlab operates in Australia (head office), the United States and the United Kingdom. For more information, please visit

medical laboratorybetter medications, best patient care


Medlab Clinic Limited

Mr. Kerem Kaya, Chief Financial Officer

Comments are closed.